Get the Stockscreener App
1.52
3.80%
-0.06
Pre-market:
1.52
Acrivon Therapeutics Inc stock is traded at $1.52, with a volume of 786.29K.
It is down -3.80% in the last 24 hours and down -9.52% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$1.58
Open:
$1.61
24h Volume:
786.29K
Relative Volume:
0.49
Market Cap:
$58.89M
Revenue:
-
Net Income/Loss:
$-77.91M
P/E Ratio:
-0.7512
EPS:
-2.0234
Net Cash Flow:
$-65.33M
1W Performance:
-7.32%
1M Performance:
-9.52%
6M Performance:
-1.30%
1Y Performance:
-71.80%
1-Day Range:
$1.52
$1.67
1-Week Range:
$1.52
$1.74
52-Week Range:
$1.05
$4.42
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.52 | 58.89M | 0 | -77.91M | -65.33M | -2.0234 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | Piper Sandler | Overweight |
| Jan-31-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-29-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| Dec-15-23 | Resumed | Jefferies | Buy |
| Oct-05-23 | Initiated | Maxim Group | Buy |
| Jun-02-23 | Initiated | Oppenheimer | Outperform |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
Citizens reiterates Acrivon Therapeutics stock rating on endometrial cancer trial progress - Investing.com
[SCHEDULE 13D/A] Acriv... - Stock Titan
Research Analysts Set Expectations for ACRV Q1 Earnings - MarketBeat
If You Invested $1,000 in Acrivon Therapeutics, Inc. (ACRV) - Stock Titan
ACRV Technical Analysis & Stock Price Forecast - Intellectia AI
Aug EndMonth: What is Acrivon Therapeutics Incs 5 year growth outlook2026 Levels & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Form 4 Acrivon Therapeutics Inc For: 4 March By Investing.com - Investing.com Australia
Acrivon Therapeutics (NASDAQ:ACRV) Releases Earnings Results, Meets Estimates - MarketBeat
Oppenheimer reiterates Acrivon stock rating on endometrial cancer focus By Investing.com - Investing.com Canada
Oppenheimer reiterates Acrivon stock rating on endometrial cancer focus - Investing.com
Acrivon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Acrivon Highlights Positive ACR-368 Data and 2025 Results - TipRanks
ACRV: 52% response rate in serous endometrial cancer and robust cash reserves support ongoing growth - TradingView
BRIEF-Acrivon Therapeutics, Inc Q4 Income From Operations USD -20.116 Million - TradingView
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Acrivon Therapeutics (ACRV) posts 2025 results, 52% ACR-368 response and $118.6M cash - Stock Titan
Cancer drug study posts 52% response as Acrivon adds new arm - Stock Titan
Acrivon Therapeutics 10-K: $0 Revenue, $(0.00) EPS, $77.9M Net Loss - TradingView
ACRV: Net loss narrowed to $77.9M in 2025; cash runway extends into Q2 2027 - TradingView
Oncology pipeline and AP3 proteomics strategy at Acrivon (NASDAQ: ACRV) - Stock Titan
ACRV Q4'25 Earnings: revenue estimate is 166.29K USD - TradingView
Acrivon Therapeutics (ACRV) Projected to Post Earnings on Thursday - MarketBeat
Acrivon Therapeutics, Inc. (ACRV) upgraded to buy: Here's why - MSN
Acrivon Therapeutics to Present Pre-Clinical Data on ACR-368 and ACR-2316 Synergy with ADCs and Immune Checkpoint Inhibitors at 2026 AACR Annual Meeting - geneonline.com
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at - GlobeNewswire
Cancer drug combo clears tumors in mice in Acrivon study - Stock Titan
Dow Update: Will Acrivon Therapeutics Inc benefit from green energy policiesTrade Entry Summary & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
EPS Watch: Is Acrivon Therapeutics Inc gaining market shareWatch List & Consistent Return Investment Signals - baoquankhu1.vn
Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Acrivon Therapeutics (ACRV) Stock Analysis Report | Financials & Insights - Benzinga Japan
Acrivon Therapeutics shares slide sharply following mixed oncology trial update - MSN
Gains Report: What is Acrivon Therapeutics Incs 5 year growth outlookWeekly Risk Summary & Real-Time Volume Analysis - baoquankhu1.vn
Acrivon Therapeutics, Inc. (ACRV) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Acrivon Therapeutics, Inc. (ACRV) Presents at ESGO 27th Annual Congress 2026Slideshow - Seeking Alpha
Acrivon Therapeutics Highlights ACR-368’s ~50% Response in Serous Endometrial Cancer at TD Cowen Conf. - Defense World
Acrivon Therapeutics (ACRV) CAO awarded 31,900 stock options at $0.00 strike - Stock Titan
Acrivon Therapeutics (ACRV) CMO granted stock options on 174,068 shares - Stock Titan
Executive Mary Miller at Acrivon Therapeutics (ACRV) granted 129,760 options - Stock Titan
Acrivon Therapeutics (ACRV) CDO awarded option on 94,946 shares - Stock Titan
Acrivon Therapeutics (ACRV) COO receives 186,728 stock options vesting from 2027 - Stock Titan
Acrivon Therapeutics (ACRV) grants stock options to CEO and EVP - Stock Titan
ACRV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Acrivon Therapeutics, Inc. (ACRV) Raised to Buy: Discover the Reasons - Bitget
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why - Yahoo Finance
Jefferies reiterates Acrivon Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Jefferies reiterates Acrivon Therapeutics stock rating on trial data - Investing.com
Acrivon Therapeutics (NASDAQ: ACRV) takes full control of ACR-368 OncoSignature - Stock Titan
What is HC Wainwright’s Estimate for ACRV FY2030 Earnings? - Defense World
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Lowered by Wall Street Zen - Defense World
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):